Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C

Hepatology

Volumn 32, Issue 3, 2000, Pages 610-617

  Baumert, Thomas F ^a,b   Wellnitz, Sabine ^a   Aono, Shigeaki ^b   Satoi, Jujin ^b   Herion, David ^b   Tilman Gerlach, J ^c   Pape, Gerd R ^c   Lau, Johnson Y N ^d   Hoofnagle, Jay H ^b   Blum, Hubert E ^a   Jake Liang, T ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HEPATITIS C ANTIBODY;

ACUTE HEPATITIS; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHRONIC HEPATITIS; CLEARANCE; CONTROLLED STUDY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ASSAY; VIRUS PARTICLE;

EID: 0033840190     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.9876     Document Type: Article

References (42)

1. Pathogenesis, natural history, treatment, and prevention of hepatitis C
2. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis
3. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
4. Flaviviridae: The viruses and their replication
5. The molecular virology of hepatitis C
6. Clinical outcomes after transfusion-associated hepatitis C
7. The prevalence of hepatitis C virus infection in the United States 1988-1994
8. Combination therapy for hepatitis C virus infection
9. The treatment of chronic viral hepatitis
10. Standards of treatment in chronic hepatitis C
11. Future options for the management of hepatitis C
12. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence
13. New perspectives in the diagnosis of hepatitis C
14. Processing and functions of hepatitis C virus proteins
15. The hepatitis C virus structural proteins assemble into virus-like particles in insect cells
16. Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate
17. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C
18. Plasmid DNA-based immunization for hepatitis C virus structural proteins: Immune responses in mice
19. Characterization of hepatitis C virus structural proteins with a recombinant baculovirus expression system
20. Expression and identification of hepatitis C virus polyprotein cleavage products
21. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
22. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection
23. Immunogenicity of variable regions of hepatitis C virus proteins: Selection and modification of peptide epitopes to assess hepatitis C virus genotypes by ELISA
24. Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: A new marker of HCV infection closely associated with viremia
25. Papillomavirus-like particles for serology and vaccine development
26. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
27. Seroreactivity to human papillomavirus types 16, 18, 31, and 45 viruslike particles in a case-control study of cervical squamous intraepithelial lesions
28. Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations
29. Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions
30. Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations
31. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees
32. Analysis of a successful immune response against hepatitis C virus
33. Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans
34. Limited humoral immunity in hepatitis C virus infection
35. Antibody responses to hepatitis C envelope proteins in patients with acute or chronic hepatitis C
36. Antibody responses to the hepatitis C virus E2 protein: Relationship to viraemia and prevalence in anti-HCV seronegative subjects
37. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C
38. Intrahepatic hepatitis C virus - Specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C
39. Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy
40. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
41. Induction of humoral and cellular immune responses in mice with insect cell-derived hepatitis C viruslike particles
42. Therapy of viral hepatitis